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A BS TR AC T
BACKGROUND
Patients with gastroesophageal reflux disease who have a partial response to pro-
ton-pump inhibitors often seek alternative therapy. We evaluated the safety and 
effectiveness of a new magnetic device to augment the lower esophageal sphincter.
METHODS
We prospectively assessed 100 patients with gastroesophageal reflux disease before 
and after sphincter augmentation. The study did not include a concurrent control 
group. The primary outcome measure was normalization of esophageal acid expo-
sure or a 50% or greater reduction in exposure at 1 year. Secondary outcomes were 
50% or greater improvement in quality of life related to gastroesophageal reflux dis-
ease and a 50% or greater reduction in the use of proton-pump inhibitors at 1 year. 
For each outcome, the prespecified definition of successful treatment was achieve-
ment of the outcome in at least 60% of the patients. The 3-year results of a 5-year 
study are reported.
RESULTS
The primary outcome was achieved in 64% of patients (95% confidence interval 
[CI], 54 to 73). For the secondary outcomes, a reduction of 50% or more in the use 
of proton-pump inhibitors occurred in 93% of patients, and there was improvement 
of 50% or more in quality-of-life scores in 92%, as compared with scores for pa-
tients assessed at baseline while they were not taking proton-pump inhibitors. The 
most frequent adverse event was dysphagia (in 68% of patients postoperatively, in 11% 
at 1 year, and in 4% at 3 years). Serious adverse events occurred in six patients, and 
in six patients the device was removed.
CONCLUSIONS
In this single-group evaluation of 100 patients before and after sphincter augmen-
tation with a magnetic device, exposure to esophageal acid decreased, reflux symp-
toms improved, and use of proton-pump inhibitors decreased. Follow-up studies 
are needed to assess long-term safety. (Funded by Torax Medical; ClinicalTrials.gov 
number, NCT00776997.)
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The fundamental pathologic abnor-mality in gastroesophageal reflux disease is an incompetent lower esophageal sphinc-
ter.1-3 First-line therapy for gastroesophageal 
reflux disease is acid suppression, usually with 
proton-pump inhibitors. Although effective, pro-
ton-pump inhibitors provide incomplete control 
of reflux symptoms in up to 40% of patients.4-6 
A partial response can occur because these drugs 
do not address an incompetent sphincter or pre-
vent reflux; consequently, some patients have only 
partial relief from symptoms and seek alternative 
treatment if their quality of life is compromised. 
At present, the only established option for these 
patients is antireflux surgery, typically Nissen 
fundoplication. However, the acceptance of sur-
gery is limited, owing to potential side effects, 
such as abdominal bloating, increased flatulence, 
inability to belch or vomit, and persistent dys-
phagia.7,8
Augmentation of the esophageal sphincter 
with a magnetic device may provide an alterna-
tive treatment for patients who have incomplete 
symptom relief with proton-pump inhibitors or 
who are reluctant to undergo surgical fundopli-
cation.9-11 The aim of magnetic sphincter aug-
mentation is to improve the barrier function of 
the sphincter without altering the hiatal and 
gastric anatomy or interfering with swallowing, 
belching, or vomiting. The feasibility of this 
concept was shown in a pilot study.11 We report 
the 3-year outcomes of a 5-year clinical trial as-
sessing the safety and effectiveness of a mag-
netic device for sphincter augmentation.
ME THODS
STUDY DESIGN
The study was designed by the sponsor (Torax 
Medical), the investigators, and the Food and Drug 
Administration as a 5-year prospective, multicenter, 
single-group evaluation of a magnetic sphincter 
device. There was no concurrent control group. 
The primary objective of the study was to evaluate 
the safety, efficacy, and direct effects of the de-
vice on exposure to esophageal acid, quality of 
life, and use of proton-pump inhibitors.
PATIENTS
Between January and September 2009, a total of 
13 centers in the United States and 1 in the Neth-
erlands enrolled patients in the study. Eligible 
patients were 18 to 75 years of age, had at least a 
6-month history of reflux disease, and had a par-
tial response to daily proton-pump inhibitors, 
with increased exposure to esophageal acid as 
confirmed by pH monitoring. Exclusion criteria 
were evidence of a large hiatal hernia, esophagi-
tis of grade C or D according to the Los Angeles 
classification (in which grade A indicates one or 
more mucosal breaks of ≤5 mm in length, grade 
B one or more mucosal breaks of >5 mm, grade 
C mucosal breaks that extend between two or 
more mucosal folds but involve <75% of the cir-
cumference of the esophagus, and grade D mu-
cosal breaks involving ≥75% of the circumfer-
ence of the esophagus), a body-mass index (BMI; 
the weight in kilograms divided by the square of 
the height in meters) of more than 35, Barrett’s 
esophagus, a motility disorder, dysphagia more 
than three times a week, and allergy to titanium, 
stainless steel, nickel, or ferrous materials. A com-
plete list of inclusion and exclusion criteria is 
provided in the study protocol, which is available 
with the full text of this article at NEJM.org.
STUDY PROCEDURES
Baseline screening included endoscopy, pH mon-
itoring while the patient was not taking proton-
pump inhibitors, barium esophagography, and 
manometry. These tests, in addition to chest ra-
diography, were repeated 1 year after implanta-
tion. Endoscopy and chest radiography were also 
performed at 2 years and are planned for 5 years. 
The dose and frequency of proton-pump inhibi-
tors, along with quality of life and foregut symp-
toms, were evaluated at baseline and postopera-
tively at 1 week, 3 months, and 6 months and 
annually starting at 1 year, with plans to contin-
ue annual screening for a total of 5 years.
Quality of life was measured with the use of 
the Gastroesophageal Reflux Disease–Health-
Related Quality of Life questionnaire, which is 
provided in the Supplementary Appendix, avail-
able at NEJM.org.12 Total scores range from 0 to 
50, with higher scores indicating worse symp-
toms, and no minimally important difference in 
scores is defined. Quality of life was assessed 
both while the patient was taking proton-pump 
inhibitors and while the patient was not taking 
proton-pump inhibitors at baseline and then 
while the patient was not taking proton-pump 
inhibitors at follow-up. Patients were asked about 
foregut symptoms, such as regurgitation, belch-
ing, and vomiting, before and after treatment.13
The esophageal sphincter device was implant-
The New England Journal of Medicine 
Downloaded from nejm.org at WASHINGTON UNIV SCH MED MEDICAL LIB on March 29, 2014. For personal use only. No other uses without permission. 
 Copyright © 2013 Massachusetts Medical Society. All rights reserved. 
esophageal Sphincter Device for gerd
n engl j med 368;8 nejm.org february 21, 2013 721
ed with the use of standard laparoscopic tech-
niques by surgeons who had experience with 
fundoplication. The device involves the use of 
magnetic attraction through adjacent magnetic 
beads, which augments the resistance of the 
esophageal sphincter to abnormal opening as-
sociated with reflux.9-11 Each bead contains a 
sealed core of magnetic neodymium iron boride 
that produces a precise and permanent force of 
attraction. The beads are connected to adjacent 
beads by small wires that allow the device to 
expand. The device is sized to fit around the 
external diameter of the esophagus, without 
compressing the underlying muscle (Fig. 1A). 
The beads separate with the transport of food or 
increased intragastric pressure associated with 
belching or vomiting (Fig. 1B; and see Video 1, 
available at NEJM.org). There were no dietary 
restrictions after implantation.
END POINTS
The primary end point was the number of pa-
tients who had normalized acid exposure (total 
proportion of time with a pH of <4 in a 24-hour 
period, ≤4.5%) or who had a reduction of 50% or 
more in the proportion of time with a pH of less 
than 4, as compared with the baseline measure-
ment while the patient was not taking proton-
pump inhibitors. The secondary end points, 
measured separately, were the number of pa-
tients with a reduction of 50% or more in the 
total score for quality of life, as compared with 
the score at baseline without proton-pump in-
hibitors, and a reduction of 50% or more in the 
dose of proton-pump inhibitors, as compared 
with the baseline dose. All efficacy end points 
were measured at 1 year, and the treatment was 
considered to be successful if the efficacy end 
points were reached in at least 60% of the pa-
tients. Safety was monitored throughout the 
study period, with assessment of the rate and 
type of serious adverse events related to the de-
vice or the implantation procedure.
STUDY OVERSIGHT
The institutional review board of each site ap-
proved the study protocol, and written informed 
consent was obtained from all patients. The data 
were analyzed by the investigators and the spon-
sor. A clinical events committee reviewed all ad-
verse events. All the authors vouch for the integ-
rity of the trial and the completeness and 
accuracy of the reported data and for the fidelity 
of this report to the study protocol. The first au-
thor wrote the initial draft of the manuscript, 
incorporating revisions from the investigators. 
The final manuscript was written by a committee 
consisting of the first author, an investigator, 
and a physician involved in study oversight, none 
of whom were employees of the sponsor. All the 
authors made the decision to submit the manu-
script for publication.
STATISTICAL ANALYSIS
All end-point analyses were performed according 
to the intention-to-treat principle, 1 year after im-
plantation. Patients who did not undergo the end-
point evaluation at 1 year or who had missing data 
were counted as having treatment failure. Addi-
tional clinical findings were assessed after 1 year 
in post hoc analyses of available data. For esopha-
geal acid monitoring, the median pH components 
at baseline and 1 year after implantation were 
compared. For quality of life, scores at baseline 
with and without proton-pump–inhibitor therapy 
were compared with scores after implantation 
without proton-pump inhibitors, along with the 
percentage of patients who said that they were sat-
isfied with their current condition at 1, 2, and 3 
years. In addition, the percentage of patients with 
complete discontinuation of proton-pump inhibi-
tors was assessed at 1, 2, and 3 years.
Continuous demographic characteristics and 
baseline variables were summarized with the 
use of standard descriptive statistics (i.e., means 
with standard deviations and medians with 
ranges). Categorical demographic characteristics 
and baseline variables were summarized by 
means of frequency distributions. A two-tailed, 
paired Student’s t-test or the Wilcoxon signed-
rank test was used to compare values before and 
after implantation. Differences were considered 
to be significant at the 0.05 level.
R ESULT S
CHARACTERISTICS OF THE PATIENTS
The study population consisted of 100 patients, 
52% of whom were men, with a median age of 53 
years (range, 18 to 75) and a median BMI of 28 
(range, 20 to 35). The median duration of reflux 
symptoms was 10 years (range, 1 to 40). The me-
dian duration of treatment with proton-pump 
inhibitors was 5 years (range, <1 to 20). Each 
patient had confirmed increased exposure to 
esophageal acid while not taking proton-pump 
Videos showing  
the placement  
and function of the 
magnetic sphincter 
are available at 
NEJM.org 
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inhibitors (median percentage of time with pH 
<4 during a median pH-monitoring period of 45 
hours, 10.9%; range, 4.8 to 25.4); the median De-
Meester score was 36.6 (range, 16.3 to 83.8). The 
DeMeester score is a composite score of factors 
quantified during a 24-to-48-hour pH study, with 
a score of 14.7 or more indicating abnormal re-
flux. Factors include the percentage of time that 
the pH was less than 4 during the assessment 
period, during the time in an upright position, 
and during the time in a supine position; the to-
tal number of reflux episodes; the number of 
episodes lasting more than 5 minutes; and the 
















Figure 1. Magnetic Device for Augmentation of the Lower Esophageal Sphincter.
Panel A shows the magnetic device in the closed position, which helps prevent opening of the lower esophageal 
sphincter and subsequent reflux. Each magnetic bead rests on adjacent beads to prevent esophageal compression. 
Panel B shows the device in the open position, which allows transport of food, belching, and vomiting.
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median quality-of-life score was 27 points with-
out proton-pump inhibitors and 11 points with 
them, indicating a partial response to proton-
pump inhibitors. A total of 98 patients complet-
ed follow-up at 1 year, 90 at 2 years, and 85 at 
3 years. A Consolidated Standards for the Re-
porting of Trials (CONSORT) diagram is provid-
ed in the Supplementary Appendix.
surgical implantation
The median time required to implant the device 
(defined as the interval between the placement of 
the last port and the removal of the first port) 
was 36 minutes (range, 7 to 125). All the implan-
tations were completed without the need to re-
vert to fundoplication. No intraoperative compli-
cations occurred. A total of 51 devices were 
placed by investigators at academic centers, and 
49 by personnel at community-based medical 
centers. All patients were discharged within 1 day 
after surgery, with an unrestricted diet.
EFFICACY END POINTS
The primary efficacy end point, normalization of 
or at least a 50% reduction in esophageal acid 
exposure, was achieved in 64% of patients (64 of 
100; 95% confidence interval [CI], 54 to 73). Of 
the patients who completed pH monitoring, 67% 
(64 of 96 patients) reached the primary efficacy 
end point (≥50% reduction in esophageal acid 
exposure in 64% [61 of 96], and normalization of 
exposure in 58% [56 of 96]). The secondary effi-
cacy end point, a 50% reduction in the quality-
of-life score, as compared with the score with-
out proton-pump inhibitors at baseline, was 
achieved in 92% of patients (92 of 100; 95% CI, 
85 to 97). In a post hoc analysis, 73% of patients 
had a reduction of 50% or more in the quality-of-
life score at 1 year, as compared with the score 
with proton-pump–inhibitor therapy at baseline. 
A reduction of 50% or more in the average daily 
dose of proton-pump inhibitors occurred in 93% 
of patients (93 of 100 patients; 95% CI, 86 to 97).
ADDITIONAL ANALYSES
Post hoc analyses of quality-of-life scores com-
pared changes in the total score and satisfaction 
level with and without proton-pump–inhibitor 
therapy. The median total score was 27 points 
without proton-pump inhibitors and 11 points 
with proton-pump inhibitors at baseline; the 
score decreased to 2 at 1 year after implantation 
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Figure 2. Quality of Life with Gastroesophageal Reflux 
Disease.
Panel A shows the median total score from the Gastro-
esophageal Reflux Disease–Health Related Quality of 
Life Scale (the main component of the scale is heart-
burn; see the Supplementary Appendix) measured at 
baseline without and with proton-pump inhibitors, as 
compared with 3 years after implantation, without pro-
ton-pump inhibitors. Total scores range from 0 to 50, 
with higher scores indicating worse symptoms. There 
was significant improvement in the median score after 
implantation for all years, as compared with baseline 
assessments both without and with proton-pump inhib-
itors (P<0.005 for the three comparisons, by the Wilcox-
on signed-rank test). Panel B shows the percentage of 
patients who reported being satisfied, neutral (neither 
satisfied nor dissatisfied), or dissatisfied with respect 
to their present condition, as assessed by means of the 
Gastroesophageal Reflux Disease–Health Related Qual-
ity of Life Scale at baseline with proton-pump inhibitors 
and at 3 years after implantation and without proton-
pump inhibitors. There was significant improvement in 
the satisfaction level for all 3 years (P<0.001 for the 
comparison of patients who were satisfied vs. those 
who were not satisfied or who had a neutral response).
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at 2 when assessed at years 2 and 3 (P<0.005 for 
all three comparisons with baseline) (Fig. 2A). 
Satisfaction with the reflux condition improved 
after implantation; 95% of patients reported sat-
isfaction at 1 year, 90% at 2 years, and 94% at 3 
years of follow-up, as compared with 13% at 
baseline (with therapy) (P<0.001 for all three 
comparisons) (Fig. 2B). There was significant im-
provement in all the individual pH components 
after implantation (Table 1). The median per-
centage of time that the pH was less than 4 while 
the patient was not receiving proton-pump in-
hibitors fell from 10.9% before implantation to 
3.3% after implantation (P<0.001). Complete ces-
sation of proton-pump inhibitors occurred in 
86% of patients (86 of 100 patients) at 1 year, in 
87% (78 of 90) at 2 years, and in 87% (72 of 83) 
at 3 years (P<0.001 for each comparison with pa-
tients reporting daily use) (Fig. 3A). Three years 
after sphincter augmentation, 13% of patients 
continued to take proton-pump inhibitors; all 
these patients took the medication at a reduced 
frequency. The proportion of patients reporting 
moderate-to-severe regurgitation decreased, from 
57% before implantation to 2% at 1 year and to 
1% at years 2 and 3 (P<0.001 for all three com-
parisons with baseline) (Fig. 3B).
SAFETY
Serious adverse events occurred in six patients 
and required removal of the device in four of the 
six. In three of the patients, the device was re-
moved at 21, 31, and 93 days after implantation 
because of persistent dysphagia, with resolution 
in all three patients after removal, and in one 
patient, the device was removed at 357 days ow-
ing to intermittent vomiting of unknown cause 
starting 3 months after implantation, without 
relief after removal. This patient had been rehos-
pitalized at 236 days after implantation for chest 
pain, nausea, and indigestion that spontaneously 
resolved. The other two patients who had serious 
adverse events required rehospitalization for nau-
sea and vomiting 2 days after surgery; their 
symptoms resolved with conservative therapy. 
The device was removed in two additional pa-
tients as part of their disease management, at 
489 days and 1062 days after implantation. One 
patient had persistent reflux symptoms, and the 
other had persistent chest pain. Three of the six 
patients in whom the device was removed subse-
quently underwent Nissen fundoplication, with 
no complications.
The most frequent adverse event was dyspha-
gia, which occurred in 68% of patients (Fig. 3C 
and Table 2). Ongoing dysphagia was noted in 
11% of patients at 1 year, in 5% at 2 years, and in 
4% at 3 years. Esophageal dilation for dysphagia 
was allowed at the discretion of the investigator. 
A total of 19 patients underwent dilation, with 16 
reporting improvement after the procedure. The 
percentage of patients with esophagitis identified 
Table 1. Components of Esophageal pH Measurements.*










Total percentage of time 100 10.9 96 3.3 <0.001
Percentage of time upright† 100 12.7 96 4.3 <0.001
Percentage of time supine‡ 98 6.0 96 0.4 <0.001
Total no. of reflux episodes 100 161.0 96 67.0 <0.001
No. of reflux episodes lasting >5 min 99 12.0 96 4.0 <0.001
Longest reflux episode (min) 99 29.0 96 13.0 <0.001
DeMeester score§ 97 36.6 96 13.5 <0.001
* All testing was performed with the use of the Bravo pH monitoring system (Given Imaging) at baseline and at 1 year.
† Time upright was defined as the time during which the patient was not recumbent.
‡ Time supine was defined as the time during which the patient was recumbent.
§ The DeMeester score is a composite score of factors quantified during a 24-to-48-hour pH study, with a score of 14.7 
or more indicating abnormal reflux. Factors include the percentage of time that the pH was less than 4 during the total 
period of assessment, during the time in an upright position, and during the time in a supine position; the total num-
ber of reflux episodes; the number of episodes lasting more than 5 minutes; and the duration of the longest episode 
(in minutes).
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at endoscopy decreased to 12% at year 1 and to 
11% at year 2, as compared with 40% at baseline 
(P<0.001 for both comparisons) (Fig. 3D). Among 
the patients without endoscopic esophagitis at 
baseline, grade A esophagitis developed in 3 at 
1 year and in 4 at 2 years. Grade D esophagitis 
developed in 1 patient at 1 year; this patient was 
asymptomatic and therefore did not take proton-
pump inhibitors, and reevaluation at 2 years 
showed complete resolution of esophagitis. Chest 
radiography and endoscopy performed at 1 year 
and at 2 years after implantation showed no evi-
dence of device migration or erosion. At 3 years, 
2 patients reported an inability to belch or vomit.
DISCUSSION
The barrier function of the lower esophageal 
sphincter depends, in part, on its ability to resist 
effacement and opening when challenged by gas-
tric distention.3,14,15 Failure to do so results in 
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Figure 3. Proton-Pump–Inhibitor Use, Reflux Symptoms, Dysphagia, and Esophagitis over the 3-Year Period.
Panel A shows the percentage of patients reporting any use of proton-pump inhibitors before and after implanta-
tion. At 3 years, 87% of the patients reported complete cessation of proton-pump inhibitors (P<0.001 for all years, 
for the comparison of daily use with no use). Panel B shows the assessment of regurgitation symptoms, according 
to the Foregut Symptom Questionnaire (see the Supplementary Appendix). Patients rated the severity of regurgita-
tion before and after treatment. Results are displayed as the percentage of patients reporting mild, moderate, or severe 
regurgitation (P<0.001 for improvement in all grades of severity, for all years). Panel C shows the percentage of pa-
tients reporting dysphagia at follow-up visits as well as the severity of the dysphagia. Any report of dysphagia after 
implantation was recorded as an adverse event. Panel D shows the percentage of patients with esophagitis, accord-
ing to grade, before and after implantation (P<0.001 for any esophagitis vs. none at both 1 and 2 years). Grading on 
the Los Angeles classification for esophagitis is as follows: grade A indicates one or more mucosal breaks of 5 mm 
or less in length, grade B one or more mucosal breaks of more than 5 mm, grade C mucosal breaks that extend be-
tween two or more mucosal folds but involve less than 75% of the circumference of the esophagus, and grade D 
mucosal breaks of 75% or more of the circumference.
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agus, which can injure the esophageal mucosa 
and underlying muscle, causing permanent dam-
age to the sphincter and leading to further loss 
of barrier function.14,16,17 Therefore, reducing 
esophageal exposure to gastric juice is an impor-
tant goal of antireflux treatment. If reflux is not 
reduced, symptoms or mucosal injury often per-
sist. Samelson et al. found that a loose ligature 
placed around the lower esophageal sphincter 
prevented the sphincter from yielding when chal-
lenged by gastric distention.15 The expandable 
magnetic device for augmentation of the sphinc-
ter builds on this observation by providing great-
er control of resistance to sphincter effacement 
and opening than is provided by previous devic-
es, allowing expansion for the passage of food, 
belching, or vomiting.
Numerous studies have shown that reflux 
symptoms persist in up to 40% of patients who 
receive therapy with proton-pump inhibitors and 
that these symptoms have a negative effect on 
both quality of life and health care utiliza-
tion.4-6,18,19 The results of the current study 
show that after magnetic sphincter augmenta-
tion, quality-of-life scores significantly improved, 
as compared with preoperative scores without or 
with proton-pump inhibitors. At 3 years, 87% of 
patients (72 of 83 patients) had completely 
eliminated the use of proton-pump inhibitors. 
These results suggest that sphincter augmenta-
tion may be helpful for patients with a partial 
response to proton-pump inhibitors.
The significant reduction in exposure to 
esophageal acid provides quantitative evidence 
that magnetic sphincter augmentation improves 
the ability of the sphincter to resist the reflux of 
gastric juice into the esophagus and is associ-
ated with sustained control of heartburn and 
regurgitation. The sustained control of regurgi-
tation implies control of both acid and nonacid 
reflux. The procedure preserved the ability to 
belch and vomit in most patients. These outcomes 
were similar in academic centers and commu-
nity centers, suggesting that the technique of 
implanting the device can be standardized. Al-
though these findings are encouraging, we rec-
ognize that they are preliminary, given the small 
study population and the 3-year follow-up.
It has long been recognized that surgical 
alteration of the lower esophageal sphincter by 
means of fundoplication may result in dyspha-
gia.13,20-23 Dysphagia also occurs after magnetic 
sphincter augmentation. In both situations, the 
postoperative dysphagia is most commonly mild 
to moderate and resolves with time. Our find-
ings suggest that the risk of dysphagia and need 
for esophageal dilation after sphincter augmen-
tation is similar to the risk after fundoplica-
tion.13,21-23 Most of the patients in our study who 
underwent dilation had improvement. We specu-
late that dilation disrupts scarring by actuating 
the beads, resulting in reduced dysphagia. After 
sphincter augmentation in this study, persistent 
dysphagia that led to the removal of the device 
developed in 3% of patients. This rate of persis-
tent dysphagia is similar to that observed in the 
pilot study and in registries in the United States 
and Europe.10,11 Removal of the device was re-
quired in six patients within 21 days to 2.9 years 










Dysphagia 68 47 16 5 3
Bloating 14 12 2 0 0
Pain 25 7 13 5 1
Odynophagia 8 4 3 1 0
Hiccups 8 7 1 0 0
Nausea 7 3 2 2 0
Inability to belch or vomit 6 5 1 0 0
Decreased appetite 4 4 0 0 0
Flatulence 2 2 0 0 0
Belching 2 2 0 0 0
Weight loss 2 2 0 0 0
Food impaction 1 0 1 0 0
Globus sensation† 1 1 0 0 0
Irritable bowel syndrome  
or dyspepsia
1 1 0 0 0
Regurgitation of sticky mucus 1 0 1 0 0
Uncomfortable feeling in chest 1 1 0 0 0
Vomiting 1 0 1 0 1
Persistent GERD symptoms‡ 1 0 1 0 1
* Mild intensity was defined as an awareness of signs or symptoms that did not 
interfere with usual activities, moderate as discomfort intense enough to 
cause interference with usual activities, and severe as incapacitating discom-
fort, with inability to perform work or usual activities.
† The globus sensation is the sensation of having a lump in the throat when no 
visible abnormality is present on examination.
‡ GERD denotes gastroesophageal reflux disease.
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after placement. The possibility of easy removal 
of the device after a longer interval is unknown.
The placement of a foreign body around a mo-
bile muscular tube such as the esophagus raises 
concern about erosion and hence the safety of the 
device. The current study, along with the previ-
ously published pilot trial11 and the commercial 
registries in the United States and Europe, brings 
the worldwide clinical experience to 497 mag-
netic implants, with a median implant duration of 
2.9 years. To date, no erosions or migrations have 
been reported. The risk over a longer period of 
follow-up is not known. The continued collection 
of data from the present study, existing registries, 
and current clinical use will allow assessment of 
the long-term risk of erosion.
The current study was designed so that the 
direct effects of the sphincter augmentation de-
vice on each patient’s exposure to esophageal 
acid, use of proton-pump inhibitors, and symp-
tom control could be measured before and after 
the implantation. This design is limited in that 
it does not allow direct comparisons with other 
forms of therapy. Prospective, randomized trials 
with appropriate controls are needed.
In conclusion, this single-group trial showed 
that a magnetic device designed to augment the 
lower esophageal sphincter can be implanted with 
the use of standard laparoscopic techniques. The 
device decreased exposure to esophageal acid, 
improved reflux symptoms, and allowed cessa-
tion of proton-pump inhibitors in the majority of 
patients. Studies with larger samples and longer-
term follow-up are needed to confirm these 
early results and assess longer-term safety.
Supported by Torax Medical.
Disclosure forms provided by the authors are available with 
the full text of this article at NEJM.org.
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